Two-week anti-Ly6G (αLy6G) treatment suppressed osteoclast and osteoblast markers in Dmp1Cre.Socs3f/f mice. (A) 6-week-old mice were injected with anti-Ly6G (αLy6G/1A8) or control (IgG) 3 times weekly for 15 days, and tissues were collected 24 hours after the last injection for analysis. (B-G) mRNA levels of osteoclast and osteoblast markers in cortical bone from control (Dmp1Cre) and Dmp1Cre.Socs3f/f mice treated with αLy6G or IgG (negative control). Shown are Tnfsf11/RANKL (B), Tnfrsf11b/osteoprotegerin (C), Sost/sclerostin (D), Dcstamp (E), Acp5 (F), and Col1a1 (G); each shown relative to housekeeping (Hprt1). Data are mean ± standard error of the mean (SEM), with individual values for each animal shown; 2-way ANOVA results, including the interaction between both factors (genotype and treatment) are shown below each graph, with P values for αLy6G treatment effect determined by post hoc test shown above each genotype group. (H) Representative raw distal femur micro-CT images for each genotype and treatment group. Scale bar, 200 μm. ANOVA, analysis of variance; micro-CT, microcomputed tomography.
